Modality
Fusion Protein
MOA
CDK4/6i
Target
BET
Pathway
Ferroptosis
Parkinson's
Development Pipeline
Preclinical
~Jun 2016
→ ~Sep 2017
Phase 1
Dec 2017
→ Jan 2030
Phase 1Current
NCT08542868
1,696 pts·Parkinson's
2017-12→2027-04·Active
NCT03094542
280 pts·Parkinson's
2023-05→2030-01·Completed
1,976 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-04-011.0y awayInterim· Parkinson's
2030-01-263.8y awayInterim· Parkinson's
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P1
Active
P1
Complet…
Catalysts
Interim
2027-04-01 · 1.0y away
Parkinson's
Interim
2030-01-26 · 3.8y away
Parkinson's
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08542868 | Phase 1 | Parkinson's | Active | 1696 | UPDRS |
| NCT03094542 | Phase 1 | Parkinson's | Completed | 280 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| RHH-1969 | Roche | Approved | BET | |
| NVS-5439 | Novartis | Preclinical | BET | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 | |
| VRT-5441 | Vertex Pharma | Phase 3 | GLP-1R | |
| Adagracapivasertib | BeiGene | NDA/BLA | BET | |
| NBI-3153 | Neurocrine | Approved | Aβ | |
| Pemicapivasertib | Legend Biotech | Phase 3 | VEGF |